212 Pb ontuxizumab conjugate - AREVA Med/MorphotekAlternative Names: 212-Pb ontuxizumab conjugate - AREVA Med/Morphotek; 212-Pb radioimmunotherapy - AREVA Med/Morphotek; Alpha radioimmunotherapy - AREVA Med/Morphotek; Lead-212 radioimmunotherapy - AREVA Med/Morphotek
Latest Information Update: 28 Apr 2016
At a glance
- Originator AREVA Med; Morphotek
- Class Drug conjugates; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours